Onco360® Has Been Selected as a National Pharmacy Partner for PIMJETMI® (pimicotinib)

On November 18, 2026 Onco360, the nation’s leading independent Specialty Pharmacy, reported it has been selected by EMD Serono for PIMJETMI (pimicotinib), indicated for the treatment of adult patients with symptomatic tenosynovial giant cell tumor (TGCT) for which surgical resection may cause worsening functional limitations or severe morbidity.

Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:

Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing

                  Schedule Your 30 min Free Demo!

"For patients whose condition makes surgery particularly challenging, access to additional treatment options is especially important. We’re proud to partner with EMD Serono and provide access to innovative treatment options that help ensure patients receive the specialized care, support, and compassion they deserve," said Benito Fernandez, Chief Commercial Officer.

PIMJETMI is a kinase inhibitor that inhibits colony-stimulating factor 1 receptor (CSF-1R). In vitro, PIMJETMI inhibited CSF-1R kinase activity and CSF-1R-dependent cell proliferation.1 The recommended PIMJETMI dosage is 50 mg orally once daily with or without food.

PIMJETMI efficacy was evaluated in the MANEUVER study (NCT05804045), a double-blind, randomized (2:1), placebo-controlled, international trial in patients with TGCT for whom surgical resection may cause dysfunction or serious complications.2 The major efficacy outcome measure was overall response rate (ORR) at Week 25. ORR was 56% (95% CI: 42, 68) in the PIMJETMI arm and 3.2% (95% CI: 0.1, 17) in the placebo arm. Median duration of response (DOR) was not reached in the PIMJETMI arm; 91% had a DOR ≥ 6 months, and 77% had a DOR ≥ 12 months. The most common (>20%) adverse reactions were pruritus, rash, facial edema, periorbital edema, fatigue, nausea, headache, and peripheral edema. The most common (>30%) lab abnormalities were increased creatine phosphokinase, increased lactate dehydrogenase, increased aspartate aminotransferase, increased lipase, increased cholesterol, amylase, and increased alanine aminotransferase.

(Press release, EMD Serono, NOV 18, 2026, View Source [SID1234674938])